141 related articles for article (PubMed ID: 36121359)
1. Physician response to COVID-19-driven telehealth flexibility for opioid use disorder.
Beetham T; Fiellin DA; Busch SH
Am J Manag Care; 2022 Sep; 28(9):456-463. PubMed ID: 36121359
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and correlates of U.S. clinicians prescribing buprenorphine for opioid use disorder treatment using expanded authorities during the COVID-19 pandemic.
Jones CM; Diallo MM; Vythilingam M; Schier JG; Eisenstat M; Compton WM
Drug Alcohol Depend; 2021 Aug; 225():108783. PubMed ID: 34049102
[TBL] [Abstract][Full Text] [Related]
3. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
4. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives.
Aronowitz SV; Engel-Rebitzer E; Dolan A; Oyekanmi K; Mandell D; Meisel Z; South E; Lowenstein M
Harm Reduct J; 2021 Nov; 18(1):119. PubMed ID: 34823538
[TBL] [Abstract][Full Text] [Related]
5. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
Cales RH; Cales SC; Shreffler J; Huecker MR
J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
[TBL] [Abstract][Full Text] [Related]
6. Impact of COVID-19 Telehealth Policy Changes on Buprenorphine Treatment for Opioid Use Disorder.
Lin LA; Zhang L; Kim HM; Frost MC
Am J Psychiatry; 2022 Oct; 179(10):740-747. PubMed ID: 35899380
[TBL] [Abstract][Full Text] [Related]
7. 'Red Flags' and 'Red Tape': Telehealth and pharmacy-level barriers to buprenorphine in the United States.
Textor L; Ventricelli D; Aronowitz SV
Int J Drug Policy; 2022 Jul; 105():103703. PubMed ID: 35561484
[TBL] [Abstract][Full Text] [Related]
8. Primary Care Providers' Experiences Treating Opioid Use Disorder Using Telehealth in the Height of the COVID-19 Pandemic.
Marshall SA; Siebenmorgen LE; Youngen K; Borders T; Zaller N
J Prim Care Community Health; 2024; 15():21501319241246359. PubMed ID: 38600789
[TBL] [Abstract][Full Text] [Related]
9. Understanding opportunities and challenges with telemedicine-delivered buprenorphine during the COVID-19 pandemic.
Mattocks KM; Moore DT; Wischik DL; Lazar CM; Rosen MI
J Subst Abuse Treat; 2022 Aug; 139():108777. PubMed ID: 35346533
[TBL] [Abstract][Full Text] [Related]
10. Medication treatment for opioid use disorder in the age of COVID-19: Can new regulations modify the opioid cascade?
Nunes EV; Levin FR; Reilly MP; El-Bassel N
J Subst Abuse Treat; 2021 Mar; 122():108196. PubMed ID: 33221125
[TBL] [Abstract][Full Text] [Related]
11. Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond.
Pessar SC; Boustead A; Ge Y; Smart R; Pacula RL
JAMA Health Forum; 2021 Nov; 2(11):e213833. PubMed ID: 35647581
[TBL] [Abstract][Full Text] [Related]
12. An examination of telehealth policy impacts on initial rural opioid use disorder treatment patterns during the COVID-19 pandemic.
Hughes PM; Verrastro G; Fusco CW; Wilson CG; Ostrach B
J Rural Health; 2021 Jun; 37(3):467-472. PubMed ID: 33720447
[TBL] [Abstract][Full Text] [Related]
13. Access to Medications for Opioid Use Disorder During COVID-19: Retrospective Study of Commercially Insured Patients from 2019-2022.
Rajagopal S; Westra J; Raji MA; Wilkes D; Kuo YF
Am J Prev Med; 2024 Apr; 66(4):635-644. PubMed ID: 37979624
[TBL] [Abstract][Full Text] [Related]
14. The Changing Nature of Telehealth Use by Primary Care Physicians in the United States.
Callaghan T; McCord C; Washburn D; Goidel K; Schmit C; Nuzhath T; Spiegelman A; Scobee J
J Prim Care Community Health; 2022; 13():21501319221110418. PubMed ID: 35795898
[TBL] [Abstract][Full Text] [Related]
15. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management.
Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR
Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331
[TBL] [Abstract][Full Text] [Related]
16. Utilization of Telehealth Solutions for Patients with Opioid Use Disorder Using Buprenorphine: A Scoping Review.
Guillen AG; Reddy M; Saadat S; Chakravarthy B
Telemed J E Health; 2022 Jun; 28(6):761-767. PubMed ID: 34714172
[No Abstract] [Full Text] [Related]
17. Defining and supporting high-quality telehealth for patients with opioid use disorder: The promise and potential pitfalls of telehealth expansion.
Frank CJ; Lin LA
Subst Abus; 2022; 43(1):1370-1373. PubMed ID: 36222798
[TBL] [Abstract][Full Text] [Related]
18. Broadband access and telemedicine adoption for opioid use disorder treatment in the United States.
Ali MM; Ghertner R
J Rural Health; 2023 Jan; 39(1):233-239. PubMed ID: 35838414
[TBL] [Abstract][Full Text] [Related]
19. The intertwined expansion of telehealth and buprenorphine access from a prescriber hub.
Moore DT; Wischik DL; Lazar CM; Vassallo GG; Rosen MI
Prev Med; 2021 Nov; 152(Pt 2):106603. PubMed ID: 33974959
[TBL] [Abstract][Full Text] [Related]
20. Telehealth acceptability and opioid prescribing patterns of providers of painful chronic diseases during the COVID-19 pandemic: A survey of sickle cell providers.
Kenney MO; Becerra B; Beatty SA; Smith WR
J Opioid Manag; 2021; 17(6):489-497. PubMed ID: 34904697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
